Warfarin and Its Pharmacogenomic Study
Warfarin as an anticoagulant is clinically prescribed to prevent blood clot formation. Genetic variants affect Warfarin response through pharmacokinetic and pharmacodynamic effects, which could account partially for the interracial difference to Warfarin. Warfarin activity is determined partially by the polymorphism in two genes, VKOPC1 and CYP2C9. Although the clinical application of pharmacogenomic information is controversial, the future gene sequencing and functional characterization of common genetic variation based on individual’s genetic information would provide a useful tool for precision medication.
KeywordWarfarin Anticoagulant Pharmacogenomics
The author would like to thank Dr. Xiaobo Wu and Dr. Ming Liu for constructive criticism and helps.
- Jensen TS, Jacques LB, Ciccanti M, Long K, Eggleston L, Roche J. Decision memo for pharmacogenomic testing for warfarin response (CAG-00400N). Centers for Medicare and Medicaid Services. 2009.Google Scholar